Application of agents of anti-PD-L1 antibody in advanced tumor therapy
10.3760/cma.j.issn.1673-422X.2016.04.015
- VernacularTitle:抗PD-L1药物在晚期肿瘤治疗中的应用
- Author:
Qiongyou JING
;
Daxun PIAO
;
Tao JIANG
;
Yuhang HUANG
;
Jianbing WANG
;
Shiqiang LI
- Publication Type:Journal Article
- Keywords:
Neoplasms;
Immunotherapy;
Programmed death ligand 1;
Checkpoint inhibitors
- From:
Journal of International Oncology
2016;43(4):296-298
- CountryChina
- Language:Chinese
-
Abstract:
Programmed death-1 (PD-1) and its ligand 1 (PD-L1) play critical roles in the identification and elimination of tumor cells evading the host's immune system.Tumor model in mice which is given anti-PD-L1 monoclonal antibody shows obviously host anti-tumor response.Currently,immunotherapy drugs of PD-1/PD-L1 signaling pathways receive good effects in a variety of tumors failure of the traditional method,and with less adverse reaction,which provide valuable clinical experiences in advanced tumor immunotherapy.
